Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

被引:133
作者
Bray, J. [1 ,2 ]
Sludden, J. [1 ]
Griffin, M. J. [1 ]
Cole, M. [1 ]
Verrill, M. [2 ]
Jamieson, D. [1 ]
Boddy, A. V. [1 ]
机构
[1] Univ Newcastle, No Inst Canc Res, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Newcastle Freeman Hosp, No Ctr Canc Care, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England
关键词
breast cancer; doxorubicin; cyclophosphamide; pharmacogenetics; MULTIDRUG-RESISTANCE; HUMAN LIVER; FUNCTIONAL-CHARACTERIZATION; IFOSFAMIDE ACTIVATION; RANDOMIZED-TRIALS; HUMAN CYP2B6; POLYMORPHISMS; PHARMACOKINETICS; IDENTIFICATION; ASSOCIATION;
D O I
10.1038/sj.bjc.6605587
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer. Doxorubicin is a substrate for ABCB1 and SLC22A16 transporters. Cyclophosphamide is a prodrug that requires oxidation to 4-hydroxy-cyclophosphamide, which yields a cytotoxic alkylating agent. The initial oxidation is catalysed by cytochrome P450 enzymes including CYP2B6, CYP2C9, CYP2C19 and CYP3A5. Polymorphic variants of the genes coding for these enzymes and transporters have been identified, which may influence the systemic pharmacology of the two drugs. It is not known whether this genetic variation has an impact on the efficacy or toxicity of AC therapy. METHODS: Germ line DNA samples from 230 patients with breast cancer on AC therapy were genotyped for the following SNPs: ABCB1 C1236T, G2677T/A and C3435T, SLC22A16 A146G, T312C, T755C and T1226C, CYP2B6* 2, *8, *9, *3, *4 and *5, CYP2C9*2 and *3, CYP3A5*3 and CYP2C19*2. Clinical data on survival, toxicity, demographics and pathology were collated. RESULTS: A lower incidence of dose delay, indicative of less toxicity, was seen in carriers of the SLC22A16 A146G, T312C, T755C variants. In contrast, a higher incidence of dose delay was seen in carriers of the SLC22A16 1226C, CYP2B6* 2 and CYP2B6*5 alleles. The ABCB1 2677A, CYP2B6*2, CYP 2B6*8, CYP 2B6*9, CYP 2B6*4 alleles were associated with a worse outcome. CONCLUSION: Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer. British Journal of Cancer (2010) 102, 1003-1009. doi:10.1038/sj.bjc.6605587 www.bjcancer.com Published online 23 February 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:1003 / 1009
页数:7
相关论文
共 50 条
  • [31] Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy
    Jamieson, David
    Cresti, Nicola
    Bray, Johanne
    Sludden, Julieann
    Griffin, Melanie J.
    Hawsawi, Nahed M.
    Famie, Eve
    Mould, Emily V. A.
    Verrill, Mark W.
    May, Felicity E. B.
    Boddy, Alan V.
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (12) : 808 - 819
  • [32] MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer
    Tormo, Eduardo
    Pineda, Begona
    Serna, Eva
    Guijarro, Alba
    Ribas, Gloria
    Fores, Jaume
    Chirivella, Enrique
    Climent, Joan
    Lluch, Ana
    Eroles, Pilar
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2015, 116 (09) : 2061 - 2073
  • [33] Gemcitabine and Platinum Pathway Pharmacogenetics in Asian Breast Cancer Patients
    Wong, Andrea Li-Ann
    Yap, Hui-Ling
    Yeo, Wee-Lee
    Soong, Richie
    Ng, Swee-Siang
    Wang, Ling-Zhi
    Cordero, Maricel Tiemsim
    Yong, Wei-Peng
    Goh, Boon-Cher
    Lee, Soo-Chin
    CANCER GENOMICS & PROTEOMICS, 2011, 8 (05) : 255 - 259
  • [34] Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients
    Chow, L. W. C.
    Biganzoli, L.
    Leo, A. D.
    Kuroi, K.
    Han, H. S.
    Patel, J.
    Huang, C. S.
    Lu, Y. S.
    Zhu, L.
    Chow, C. Y. C.
    Loo, W. T. Y.
    Gluck, S.
    Toi, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (06) : 372 - 378
  • [35] Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer
    Perez-Ortiz, Andric C.
    Ramirez, Israel
    Cruz-Lopez, Juan C.
    Villarreal-Garza, Cynthia
    Luna-Angulo, Alexandra
    Lira-Romero, Esmeralda
    Jimenez-Chaidez, Salvador
    Diaz-Chavez, Jose
    Matus-Santos, Juan A.
    Sanchez-Chapul, Laura
    Mendoza-Lorenzo, Patricia
    Estrada-Mena, Francisco J.
    ONCOTARGET, 2017, 8 (63) : 106454 - 106467
  • [36] Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study
    Gadisa, Diriba Alemayehu
    Assefa, Mathewos
    Wang, Shu-Hua
    Yimer, Getnet
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (08) : 1912 - 1920
  • [37] Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients
    Tang, Nelson L. S.
    Liao, Chen Di
    Wang, Xingyan
    Mo, Frankie K. F.
    Chan, Vicky T. C.
    Ng, Rita
    Pang, Elizabeth
    Suen, Joyce J. S.
    Woo, Jean
    Yeo, Winnie
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (03) : 419 - 427
  • [38] Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review
    Chen, Sylvia
    Sutiman, Natalia
    Zhang, Clara Zhenxian
    Yu, Yingnan
    Lam, Shirley
    Khor, Chiea Chuen
    Chowbay, Balram
    DRUG METABOLISM REVIEWS, 2016, 48 (04) : 502 - 540
  • [39] Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy
    Tsuji, Daiki
    Matsumoto, Megumi
    Kawasaki, Yohei
    Kim, Yong-I. L.
    Yamamoto, Keisuke
    Nakamichi, Hidenori
    Sahara, Yuri
    Makuta, Ryo
    Yokoi, Mari
    Miyagi, Takehiro
    Itoh, Kunihiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 73 - 83
  • [40] Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients.
    Saeki T.
    Takashima S.
    Ogita M.
    Tabei T.
    Adachi I.
    Tamura K.
    Takatsuka Y.
    Kanda K.
    Breast Cancer, 2006, 13 (2) : 159 - 165